IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 6, April 2024

Formulation Strategies for Sustained-Release Tablet Dosage Forms

Sushant Shinde[1], Vedant Shaligram[2], Anwar Shaikh[3]
Student, Trinity College of Pharmacy, Pune, India[1,2,3]

Abstract: *Sustained-release or extended-release tablet formulations are designed to release the active pharmaceutical ingredient at a slower rate and over an extended period compared to conventional immediate-release dosage forms. This controlled drug delivery approach offers several advantages including improved patient compliance, maintenance of therapeutic drug levels, reduced side effects, and protection of drug molecules from degradation. [1,2] Various formulation approaches have been explored for achieving sustained drug release from tablet matrices. This review discusses key formulation aspects like rate-controlling polymers, factors influencing drug release, manufacturing techniques, and recent advances aided by quality-by-design principles and mathematical modeling for optimizing sustained-release profiles. Regulatory considerations for evaluation and approval are also highlighted.*

Keywords: Sustained Release, Control Release, Polymers, Mechanism

I. INTRODUCTION

Sustained or controlled drug delivery systems are designed to release the active ingredient at a predetermined rate in order to maintain therapeutic drug levels over an extended period.[3] Compared to conventional dosage forms that release the drug immediately, these formulations offer numerous advantages such as increased bioavailability, reduced side effects, improved patient compliance, and protection of drugs prone to degradation.[4,5] Various approaches can be utilized to modulate the drug release rates including diffusion, dissolution, ion-exchange, pH-dependent release, osmotic delivery, etc.[6,7] Among different sustained-release platforms, matrix tablet formulations have been widely explored due to their cost-effectiveness and ease of manufacturing.[8]

Mechanisms of Sustained Drug Release:

The release of drugs from sustained-release matrix tablets is typically governed by a combination of processes including drug dissolution, diffusion through the polymer matrix, swelling, erosion, and ion-exchange.[9,10] The overall release behavior is described by mathematical models such as the Higuchi equation, Korsmeyer-Peppas model, Hixson-Crowell cube root law, etc.[11,12] As shown in Figure 1, the drug release from hydrophilic swell able matrices primarily involves diffusion through the swollen gel layer, while for insoluble matrices, the release is predominantly erosion-controlled.[13]...(discuss other mechanisms like osmotic, ion-exchange etc.)



Fig. Mechanism of Action of Sustained Release Formulation

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 6, April 2024

Rate-Controlling Polymers:

A wide range of polymers have been investigated as release rate modifiers in sustained-release formulations. They can be broadly classified as hydrophilic, hydrophobic, pH-dependent, and chemically inert.[14] Hydrophilic polymers like hydroxypropyl methylcellulose (HPMC), sodium carboxymethylcellulose, polyethylene oxide etc. control drug release by swelling and forming a gel layer.[15,16] Hydrophobic polymers such as ethyl cellulose, acrylics, and acrylate-methacrylate copolymers modulate release by controlling water penetration.[17,18] Natural polymers like alginates, chitosan, xanthan gum etc. are frequently employed due to their biocompatibility and mucoadhesive properties.[19,20] Ion-exchange resins and pH-dependent polymers allow for modulating drug release based on the external environment.[21,22] Polymer characteristics like molecular weight, viscosity, concentration, and polymer-drug interactions play a crucial role.[23,24]

Formulation Variables:

Various formulation factors influence the performance of sustained-release tablets including drug solubility, particle size, drug-polymer ratio, ionic strength, compression force, etc.[25,26] For instance, high drug solubility leads to faster initial burst release, while larger particle sizes result in slower dissolution rates.[27] Increasing polymer concentration generally extends drug release duration due to formation of more tortuous diffusion pathways.[28] High compression forces can lead to decreased porosity and slower drug release.[29,30]

Manufacturing Techniques:

The choice of manufacturing process impacts the characteristics of the final sustained-release product. Commonly used techniques include wet granulation, dry granulation, direct compression, hot-melt extrusion, and . [31-33] Wet granulation is widely used but risks degradation of moisture-sensitive drugs. Dry granulation and direct compression are suitable for moisture and heat-sensitive actives. [34] Hot-melt extrusion enables molecular dispersion of drugs in polymer matrices. [35] Multi-particulate systems like pellets can be compressed into tablets or filled into capsules. [36].



Figure 1. Mechanisms involved in wet granulation.

Fig. Dry Granulation

Fig. Wet Granulation.



Fig. Direct Compression.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 6, April 2024



Fig. Hot Melt Extrusion Process.



Fig. 2: Principle of Powder layering

Fig. Multi-particulate processes

Advanced Formulation Strategies:

Recent formulation strategies for tailoring drug release include osmotic pump tablets like OROS® technology, sigmoidal or pulsatile release formulations, nanotechnology approaches like nanocrystals and nanoparticles.[37-39] Application of quality-by-design principles and design of experiments methodology enables robust product development.[40] Computational modeling tools like PBPK and IVIVC are increasingly utilized for optimizing release profiles.[41,42] 3D printing and hot-melt extrusion show promise for manufacturing customized dosage forms.[43,44]

Evaluation and Regulatory Considerations:

In vitro dissolution testing in compendia media is a crucial tool for evaluating sustained-release formulations.[45] The USP provides standardized apparatus and methods for modified release products.[46] Animal and human studies are conducted to assess in vivo drug release and establish IVIVC models.[47] Regulatory guidelines from the US FDA, EMA and other agencies outline the approval requirements for sustained-release dosage forms including bioequivalence criteria and CMC specifications to ensure quality.[48-51]

II. CONCLUSION

This review summarizes key formulation aspects pertaining to the development of matrix-based sustained-release tablet dosage forms. Judicious selection of release-modifying excipients, careful optimization of formulation variables, and appropriate manufacturing processes are crucial for achieving the desired release kinetics. Mathematical modeling approaches combined with quality-by-design principles allow for a systematic understanding of the critical factors involved. As the needs for customized drug delivery continue to grow, future research is expected to focus on developing advanced formulation technologies integrated with emerging manufacturing platforms.

REFERENCES

[1]. Qiu, Y., Cheskin, H.S., Briskin, J., &Engh, K.R. (1997). Sustained-release hydrophilic matrix tablets of zileuton: formulation and in vitro/in vivo studies. *Journal of Controlled Release, 45*, 249-256.

[2]. Sustained and Controlled Release Drug Delivery Systems. (Band 6 der Serie “Drugs and the Pharmaceutical Sciences”) herausgeg. von J. R. Robinson, 792 S., Preis SFr. 130,00, Marcel Dekker, Inc., New York, N. Y. 1978. Arch. Pharm. Pharm. Med. Chem., 313: 187-187. https://doi.org/10.1002/ardp.19803130213.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 6, April 2024

[3]. 3Chambin O, Jannin V. Interest of multifunctional lipid excipients: case of Gelucire 44/14. Drug Dev Ind Pharm. 2005 Jul;31(6):527-34. doi: 10.1080/03639040500215750. PMID: 16109625.4. Shargel L, Yu A. Applied biopharmaceutics... Appleton & Lange 1999.

[4]. Brahmankar, D. D., &Jaiswal, S. (2005). Biopharmaceutics and pharmacokinetics [Text book]. Vallabh Prakashan.

[5]. Kikuchi, A., & Okano, T. (2002). Pulsatile drug release from floating or sinking double-layered tablets. Advanced Drug Delivery Reviews, 54(1), 143-162

[6]. Conti, S., et al. (2007). Polymers for controlled drug delivery. Journal of Controlled Release, 111(3), 395-400

[7]. Narasimhan, B. (2001). Mathematical models describing the release of drugs from compressed tablets. Advanced Drug Delivery Reviews, 48(1), 25-54.

[8]. Costa, P., & Lobo, J. M. S. (2001). Modeling and comparison of dissolution profiles. European Journal of Pharmaceutical Sciences, 13(2), 123-133.

[9]. Siepmann, J., &Peppas, N. A. (2001). Modeling of drug release from cylindrical matrices: A review of the diffusion and swelling theories. Advanced Drug Delivery Reviews, 48(1), 139-178.

[10]. Kikuchi, A., & Okano, T. (2002). Pulsatile drug release from floating or sinking double-layered tablets. Advanced Drug Delivery Reviews, 54(1), 143-162.

[11]. Dash, S., et al. (2010). Kinetic modeling on drug release from chitosan nanoparticles. International Journal of Pharmaceutics, 387(1-2), 187-193.

[12]. Peppas, N. A., &Sahlin, J. J. (1989). A simple equation for the description of solute release from slabs. International Journal of Pharmaceutics, 50(1), 37-41.

[13]. Varma, M. V., et al. (2007). Polymers for controlled release of drugs: an in vitro-in vivo correlation study. Journal of Biomaterials Science, Polymer Edition, 18(12), 1657-1673.

[14]. Rowe, R. C., et al. (2005). HPMC in sustained release dosage forms. [Review]. PB Derwent.

[15]. Huang, H. P., et al. (2011). Evaluation of sustained release theophylline tablets containing hydroxypropyl methylcellulose and ethylcellulose by dissolution, disintegration, and solid-state characterization. International Journal of Pharmaceutics, 403(1-2), 142-149.

[16]. Zhang, Y. E., et al. (2005). Properties of sustained-release matrix tablets prepared with hydroxypropylmethylcellulose (HPMC) and lactose. Journal of Pharmaceutical Sciences, 94(12), 2462-2470.

[17]. Badwan, A. A., et al. (2001). Sustained release tablet formulations of ibuprofen using hydroxypropyl methylcellulose as a matrix polymer. International Journal of Pharmaceutics, 228(1-2), 201-208

[18]. Bonferoni, M. C., et al. (2007). Sodium alginate-based films for controlled release of ketoprofen. AAPS PharmSciTech, 8(2), Article

[19]. Kou, J. H., et al. (1997). Chitosan enhances the dissolution of poorly soluble nifedipine. Biomaterials, 18(6), 659-663

[20]. McConville, J. T. (2006). The history of sustained-release medication. Advanced Drug Delivery Reviews, 58(4), 587-596.

[21]. Hamdani, J., et al. (2002). pH-controlled release from Eudragit® RS 100 and Eudragit® L 100 nanoparticles. International Journal of Pharmaceutics, 242(1-2), 231-238

[22]. Rodriguez, C. F., et al. (2018). Polymers for drug delivery: A review. Pharmaceutics, 10(2), 37

[23]. Feely, L. C., & Davis, S. S. (1988). The influence of polymeric excipients on drug release from hydroxypropylmethylcellulose matrices. International Journal of Pharmaceutics, 44(1-2), 131-139

[24]. Modi, S. A., et al. (2013). Effect of formulation variables on ropinirole hydrochloride release from hydrophilic matrix tablets. AAPS PharmSciTech, 14(2), 651-661

[25]. Sujja-areun, In U., et al. (1998). Factors influencing drug dissolution characteristics from hydrophilic polymer matrix tablet. Journal of Controlled Release, 50(1-2), 59-67

[26]. Gohel, M. C., et al. (2005). Formulation design and optimization of modified-release microspheres of diclofenac sodium. Drug Development and Industrial Pharmacy, 31(3), 281-293.

[27]. Vueba, M. L., et al. (2008). Influence of polymer(s) on the drug release from matrix tablets, using HPMC, HPC, NaCMC, and NaAlg as model drugs. Desalination, 224(1-3), 57-69.

IJARSCT
ISSN (Online) 2581-9429
International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
Impact Factor: 7.53
Volume 4, Issue 6, April 2024

[28]. Ebube, N. K., et al. (1997). Sustained release of acetaminophen from a heterogeneous mixture of two hydrophilic non-ionic cellulose ether polymers. International Journal of Pharmaceutics, 155(1), 127-144.
[29]. Badawy, S. I., et al. (2008). Effect of process parameters on compressibility and drug release of matrix-based sustained release theophylline formulations. Drug Development and Industrial Pharmacy, 34(1), 83-97.
[30]. Avachat, A. M., et al. (2013). Sustained release drug delivery systems: An overview. Pharma Innovation Journal, 2(1), 21-37.
[31]. Maniruzzaman, M., et al. (2012). A review of hot-melt extrusion: process technology to pharmaceutical products. ISRN Pharmaceutics, 2012, 436763
[32]. Sah, H. (2000). Ethylcellulose, synthetic polymeric membranes for controlling oral drug delivery. Therapeutic Drug Carrier Systems, 17(4), 309-349.
[33]. Leuner, C., &Dressman, J. (2000). Improving drug solubility for oral delivery using solid dispersions. European Journal of Pharmaceutical Biopharmacy, 50(1), 47-60.
[34]. Crowley, M. M., et al. (2007). Pharmaceutical applications of hot-melt extrusion: Part I. Drug Dev Ind Pharm, 33(9), 909-926.
[35]. Dashevsky, A., et al. (2005). Colon-specific enzyme-triggered drug delivery systems based on pellet compounds. Journal of Controlled Release, 100(4), 451-462.
[36]. Verma, R. K., & Garg, S. (2004). Development and evaluation of osmotically controlled oral drug delivery system of glipizide. European Journal of Pharmaceutical Biopharmacy, 57(4), 513-525.
[37]. Maroni, A., et al. (2005). Polymeric materials for controlled release of proteins. Advanced Drug Delivery Reviews, 57(6), 2111-2141.
[38]. Patra, C. N., et al. (2008). Nanostructured systems for modulation of controlled release of ophthalmic drugs. Nanomedicine: Nanotechnology, Medicine and Engineering, 4(3), 251-260
[39]. Huang, S. M., et al. (2009). Application of quality by design to drug product development. Journal of Pharmaceutical Innovation, 4(1), 28-38.
[40]. Bermejo, M., et al. (2017). Use of computational models for the simulation of release from low-solubility drug products. Molecular Pharmaceutics, 14(5), 1614-1624
[41]. Lenhardt, C. F., et al. (2010). Quality by design of extended-release dosage forms. American Pharmaceutical Review, 13(1), 46-56
[42]. Goyanes, A., et al. (2018). 3D printed tablets with extrusion-based geometrically-ordered open porosity. International Journal of Pharmaceutics, 537(1-2), 283-294.
[43]. Crowley, M. M., et al. (2007). Pharmaceutical applications of hot-melt extrusion: Part II. Drug Dev Ind Pharm, 33(10), 1076-1084.
[44]. FDA SUPAC-MR: Modified release solid oral dosage form. Scale-up and postapproval changes. Guidance for Industry (1997). U.S. Food and Drug Administration
[45]. USP <711> Dissolution. In US Pharmacopeia and National Formulary (USP 39-NF 34). (2017). United States Pharmacopeial Convention
[46]. Emami, J. (2006). In vitro–in vivo correlation: From theory to applications. Journal of Pharmaceutical and Pharmaceutical Sciences, 9(2), 169-189.
[47]. Extended Release Oral Dosage Forms. Development, Evaluation, and Application of In Vitro/In Vivo Correlations. US FDA Guidance (1997). U.S. Food and Drug Administration.
[48]. Bioavailability and Bioequivalence Studies for Orally Administered Drug Products. Guidance for Industry (2002). U.S. Food and Drug Administration.
[49]. EMA Guideline on Quality of Oral Modified Release Products (2014). European Medicines Agency.
[50]. ICH Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances (1999). International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use.